Table 3 Clinical features of CM based on ICHD-3β and EO criteria
From: Field testing of the ICHD-3β and expert opinion criteria for chronic migraine
ICHD-3β | EO | P-value | |
|---|---|---|---|
n = 185 | n = 261 | ||
Age (years), mean (SD) | 48.5 ± 11.4 | 49.54 ± 11.5 | 0.364 |
Gender, n (%) | 0.837 | ||
Female | 137 (74.1 %) | 191 (73.2 %) | |
Male | 48 (24.9 %) | 70 (26.8 %) | |
BMI, mean (SD) | 23.2 ± 3.7 | 22.9 ± 3.6 | 0.418 |
Educational level, n (%) | 0.783 | ||
< high school | 149 (77.8 %) | 206 (78.9 %) | |
≥ high school | 42 (22.2 %) | 55 (21.1 %) | |
Frequency of headache days, mean (SD) | 23.5 ± 6.4 | 23.7 ± 6.4 | 0.750 |
Frequency of migraine days, mean (SD) | 19.9 ± 7.9 | 20.4 ± 7.9 | 0.519 |
Age of onset of migraine, mean (SD) | 31.7 ± 12.1 | 32.1 ± 12.4 | 0.727 |
Courses of migraine, mean (SD) | 16.8 ± 10.9 | 17.4 ± 11.7 | 0.588 |
Age of onset of CM, mean (SD) | 42.3 ± 12.0 | 42.9 ± 12.1 | 0.624 |
Courses of CM, mean (SD) | 6.2 ± 8.2 | 6.8 ± 8.4 | 0.503 |
Currently used acute analgesics, n (%) | 0.811 | ||
Yes | 154 (83.2 %) | 215 (82.5 %) | |
No | 31 (16.8 %) | 46 (17.6 %) | |
Category of used analgesics, n (%) | 0.773 | ||
Single analgesics | 9 (5.8 %) | 14 (6.5 %) | |
Combination analgesics | 81 (52.6 %) | 105 (48.8 %) | |
Multiple analgesics | 64 (41.6 %) | 96 (44.7 %) | |
Ergots | 0 | 0 | |
Triptans | 1 (0.6 %) | 1 (0.5 %) | 0.813 |
Medication overuse, n (%) | 0.964 | ||
Yes | 123 (66.5 %) | 173 (66.3 %) | |
No | 62 (33.5 %) | 88 (33.7 %) | |
Family headache history, n (%) | 0.995 | ||
Yes | 100 (54.1 %) | 141 (54.0 %) | |
No | 85 (45.9 %) | 120 (46.0 %) | |